A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma

BACKGROUND: Influenza virus (IFV) infection is associated with increased morbidity and mortality in people with underlying lung disease. Treatment options for IFV are currently limited and antiviral resistance is a growing concern. DAS181, an inhaled antiviral with a unique mechanism of action, has...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Rhonda E., Fiorentino, Charles, Dodd, Lori E., Hunsberger, Sally, Haney, Carissa, Barrett, Kevin, Nabha, Linda, Davey Jr., Richard T., Olivier, Kenneth N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736611/
https://www.ncbi.nlm.nih.gov/pubmed/26830468
http://dx.doi.org/10.1186/s12879-016-1358-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736611/
https://www.ncbi.nlm.nih.gov/pubmed/26830468
http://dx.doi.org/10.1186/s12879-016-1358-9

Ejemplares similares